LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Health & Fitness
• Education
• Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, article, lung, prognostic, google, scholar, patients, advanced, factors, clin, survival, model, gemcitabine, oncol, cas, nonsmallcell, pubmed, count, cell, access, research, leukocyte, nonsmall, status, group, phase, iii, privacy, cookies, content, journal, elevated, blood, poor, tibaldi, chemotherapy, performance, metastatic, metastases, study, versus, analysis, publish, search, oncology, peripheral, vasile, bernardini, falcone, stage,

Topics {✒️}

month download article/chapter small-cell lung cancer high-risk patients achieved independent prognostic factors elevated leukocyte count series prognostic factors leukocyte count resulted phase iii trial proposed prognostic model risk-stratification model full article pdf privacy choices/manage cookies clinical oncology aims prognostic factors multivariate analysis cumulative risk defined simplified risk scores tumor-related leukocytosis retrospective cohort study contralateral lung metastases related subjects prognostic model european economic area nsclc patients treated generation chemotherapy regimens check access instant access lung carcinoma model based carboplatin versus gemcitabine scope submit manuscript gonzalez-larriba jl de las penas poor prognosis ecog performance status conditions privacy policy multivariate cox specific future trials von der maase santa chiara hospital article journal herbst rs vinorelbine versus gemcitabine cancer research accepting optional cookies journal finder publish main content log stage iiib-iv nsclc patients prognostic significance

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model
         description:We aimed to investigate the prognostic significance of several baseline variables in stage IIIB-IV non-small cell lung cancer to create a model based on independent prognostic factors. A total of 320 patients were treated with last generation chemotherapy regimens. The majority of patients received treatment with cisplatin + gemcitabine or gemcitabine alone if older than 70 years or with an ECOG performance status (PS) = 2. Performance status of 2, squamous histology, number of metastatic sites >2, presence of bone, brain, liver and contralateral lung metastases and elevated leukocyte count in peripheral blood were all statistically significant prognostic factors in univariate analyses whereas the other tested variables (sex, stage, age, presence of adrenal gland and skin metastases) were not. Subsequently, a multivariate Cox’s regression analysis identified PS 2 (P < 0.001, hazard ratio 2.57), elevated leukocyte count (P < 0.001, hazard ratio 1.79), squamous histology (P = 0.005, hazard ratio 1.45) and presence of brain metastases (P = 0.035, hazard ratio 1.5) as independent prognostic factors for poor survival. Patients were assigned to one of three risk groups according to the cumulative risk defined as the sum of simplified risk scores of the four independent prognostic factors. Low-, intermediate- and high-risk patients achieved a median survival of 10.2 months (95% confidence interval (CI) 8.9–11.6), 5.1 months (95% CI 4.0–6.2) and 2.8 months (95% CI 0.5–5.2), respectively. The high-risk group encompassed PS 2 patients with two or three adjunctive unfavourable independent prognostic factors. Performance status, white blood cells count, histology and brain metastases resulted in our series prognostic factors of survival in NSCLC patients treated with chemotherapy at a multivariate analysis. Leukocyte count resulted the stronger factor after performance status. If prospectly validated, the proposed prognostic model could be useful to stratify performance status 2 patients in specific future trials.
         datePublished:2008-03-18T00:00:00Z
         dateModified:2008-03-18T00:00:00Z
         pageStart:1143
         pageEnd:1149
         sameAs:https://doi.org/10.1007/s00432-008-0378-2
         keywords:
            Leukocyte count
            Multivariate analysis
            Prognostic factors
            Prognostic model
            NSCLC
            Chemotherapy
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-008-0378-2/MediaObjects/432_2008_378_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-008-0378-2/MediaObjects/432_2008_378_Fig2_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:134
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:C. Tibaldi
               affiliation:
                     name:Civil Hospital
                     address:
                        name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:E. Vasile
               affiliation:
                     name:Civil Hospital
                     address:
                        name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:I. Bernardini
               affiliation:
                     name:Civil Hospital
                     address:
                        name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Orlandini
               affiliation:
                     name:Santa Chiara Hospital
                     address:
                        name:Division of Medical Oncology, Santa Chiara Hospital, Pisa, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Andreuccetti
               affiliation:
                     name:Civil Hospital
                     address:
                        name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Falcone
               affiliation:
                     name:Civil Hospital
                     address:
                        name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Pisa
                     address:
                        name:University of Pisa, Pisa, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Tumori Toscano (ITT)
                     address:
                        name:Istituto Tumori Toscano (ITT), Firenze, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model
      description:We aimed to investigate the prognostic significance of several baseline variables in stage IIIB-IV non-small cell lung cancer to create a model based on independent prognostic factors. A total of 320 patients were treated with last generation chemotherapy regimens. The majority of patients received treatment with cisplatin + gemcitabine or gemcitabine alone if older than 70 years or with an ECOG performance status (PS) = 2. Performance status of 2, squamous histology, number of metastatic sites >2, presence of bone, brain, liver and contralateral lung metastases and elevated leukocyte count in peripheral blood were all statistically significant prognostic factors in univariate analyses whereas the other tested variables (sex, stage, age, presence of adrenal gland and skin metastases) were not. Subsequently, a multivariate Cox’s regression analysis identified PS 2 (P < 0.001, hazard ratio 2.57), elevated leukocyte count (P < 0.001, hazard ratio 1.79), squamous histology (P = 0.005, hazard ratio 1.45) and presence of brain metastases (P = 0.035, hazard ratio 1.5) as independent prognostic factors for poor survival. Patients were assigned to one of three risk groups according to the cumulative risk defined as the sum of simplified risk scores of the four independent prognostic factors. Low-, intermediate- and high-risk patients achieved a median survival of 10.2 months (95% confidence interval (CI) 8.9–11.6), 5.1 months (95% CI 4.0–6.2) and 2.8 months (95% CI 0.5–5.2), respectively. The high-risk group encompassed PS 2 patients with two or three adjunctive unfavourable independent prognostic factors. Performance status, white blood cells count, histology and brain metastases resulted in our series prognostic factors of survival in NSCLC patients treated with chemotherapy at a multivariate analysis. Leukocyte count resulted the stronger factor after performance status. If prospectly validated, the proposed prognostic model could be useful to stratify performance status 2 patients in specific future trials.
      datePublished:2008-03-18T00:00:00Z
      dateModified:2008-03-18T00:00:00Z
      pageStart:1143
      pageEnd:1149
      sameAs:https://doi.org/10.1007/s00432-008-0378-2
      keywords:
         Leukocyte count
         Multivariate analysis
         Prognostic factors
         Prognostic model
         NSCLC
         Chemotherapy
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-008-0378-2/MediaObjects/432_2008_378_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-008-0378-2/MediaObjects/432_2008_378_Fig2_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:134
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:C. Tibaldi
            affiliation:
                  name:Civil Hospital
                  address:
                     name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:E. Vasile
            affiliation:
                  name:Civil Hospital
                  address:
                     name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:I. Bernardini
            affiliation:
                  name:Civil Hospital
                  address:
                     name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Orlandini
            affiliation:
                  name:Santa Chiara Hospital
                  address:
                     name:Division of Medical Oncology, Santa Chiara Hospital, Pisa, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Andreuccetti
            affiliation:
                  name:Civil Hospital
                  address:
                     name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Falcone
            affiliation:
                  name:Civil Hospital
                  address:
                     name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Pisa
                  address:
                     name:University of Pisa, Pisa, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Tumori Toscano (ITT)
                  address:
                     name:Istituto Tumori Toscano (ITT), Firenze, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:134
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Civil Hospital
      address:
         name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
      name:Civil Hospital
      address:
         name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
      name:Civil Hospital
      address:
         name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
      name:Santa Chiara Hospital
      address:
         name:Division of Medical Oncology, Santa Chiara Hospital, Pisa, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
      name:Civil Hospital
      address:
         name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
      name:Civil Hospital
      address:
         name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
         type:PostalAddress
      name:University of Pisa
      address:
         name:University of Pisa, Pisa, Italy
         type:PostalAddress
      name:Istituto Tumori Toscano (ITT)
      address:
         name:Istituto Tumori Toscano (ITT), Firenze, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:C. Tibaldi
      affiliation:
            name:Civil Hospital
            address:
               name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:E. Vasile
      affiliation:
            name:Civil Hospital
            address:
               name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
      name:I. Bernardini
      affiliation:
            name:Civil Hospital
            address:
               name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
      name:C. Orlandini
      affiliation:
            name:Santa Chiara Hospital
            address:
               name:Division of Medical Oncology, Santa Chiara Hospital, Pisa, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
      name:M. Andreuccetti
      affiliation:
            name:Civil Hospital
            address:
               name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
      name:A. Falcone
      affiliation:
            name:Civil Hospital
            address:
               name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
               type:PostalAddress
            type:Organization
            name:University of Pisa
            address:
               name:University of Pisa, Pisa, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Tumori Toscano (ITT)
            address:
               name:Istituto Tumori Toscano (ITT), Firenze, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
      name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
      name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
      name:Division of Medical Oncology, Santa Chiara Hospital, Pisa, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
      name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
      name:Division of Medical Oncology, Civil Hospital, Livorno, Italy
      name:University of Pisa, Pisa, Italy
      name:Istituto Tumori Toscano (ITT), Firenze, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(72)

• How much income is https://www.springernature.com/gp/authors earning monthly?
• What's the total monthly financial gain of https://link.springernature.com/home/?
• What's the monthly money flow for https://order.springer.com/public/cart?
• How much does https://submission.nature.com/new-submission/432/3 generate monthly?
• Learn how profitable https://www.springernature.com/gp/librarians/licensing/agc/journals is on a monthly basis
• Monthly income for https://doi.org/10.1200%2FJCO.2003.12.038
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=Cisplatin%20plus%20gemcitabine%20versus%20a%20cisplatin-based%20triplet%20versus%20nonplatinum%20sequential%20doublets%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20Spanish%20lung%20cancer%20group%20phase%20III%20randomized%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2003.12.038&volume=17&pages=3207-3213&publication_year=2003&author=Alberola%2CV&author=Camps%2CC&author=Provencio%2CM&author=Isla%2CD&author=Rosell%2CR&author=Vadell%2CC&author=Bover%2CI&author=Ruiz-Casado%2CA&author=Azagra%2CP&author=Jimenez%2CU&author=Gonzalez-Larriba%2CJL&author=Diz%2CP&author=Cardenal%2CF&author=Artal%2CA&author=Carrato%2CA&author=Morales%2CS&author=Sanchez%2CJJ&author=las%20Penas%2CR&author=Felip%2CE&author=Lopez-Vivanco%2CG each month?
• https://doi.org/10.1038%2Fsj.bjc.6600768 income
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12569375 make?
• How much does http://scholar.google.com/scholar_lookup?&title=Metastatic%20renal%20carcinoma%20comprehensive%20prognostic%20system&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6600768&volume=88&pages=348-353&publication_year=2003&author=Atzpodien%2CJ&author=Royston%2CP&author=Wandert%2CT&author=Reitz%2CM rake in every month?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=New%20chemotherapeutic%20agents%20prolong%20survival%20and%20improve%20quality%20of%20life%20in%20non-small%20cell%20lung%20cancer%3A%20a%20review%20of%20the%20literature%20and%20future%20directions&journal=Clin%20Cancer%20Res&volume=4&pages=1087-1100&publication_year=1998&author=Bunn%2CPA&author=Kelly%2CK?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Regression%20models%20and%20life%20tables&journal=J%20R%20Stat%20Soc&volume=34&pages=187-220&publication_year=1972&author=Cox%2CDR?
• How much revenue does https://doi.org/10.1200%2FJCO.2004.08.001 produce monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14990632 earn?
• How much money does http://scholar.google.com/scholar_lookup?&title=Gefitinib%20in%20combination%20with%20gemcitabine%20and%20cisplatin%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20phase%20III%20trial%E2%80%93INTACT%201&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2004.08.001&volume=22&pages=777-784&publication_year=2004&author=Giaccone%2CG&author=Herbst%2CRS&author=Manegold%2CC&author=Scagliotti%2CG&author=Rosell%2CR&author=Miller%2CV&author=Natale%2CRB&author=Schiller%2CJH&author=Pawel%2C&author=Pluzanska%2CA&author=Gatzemeier%2CU&author=Grous%2CJ&author=Ochs%2CJS&author=Averbuch%2CSD&author=Wolf%2CMK&author=Rennie%2CP&author=Fandi%2CA&author=Johnson%2CDH generate?
• How much income does https://doi.org/10.1200%2FJCO.2004.07.215 have?
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14990633?
• How much does http://scholar.google.com/scholar_lookup?&title=Gefitinib%20in%20combination%20with%20paclitaxel%20and%20carboplatin%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20phase%20III%20trial%E2%80%93INTACT%202&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2004.07.215&volume=22&pages=785-794&publication_year=2004&author=Herbst%2CRS&author=Giaccone%2CG&author=Schiller%2CJH&author=Natale%2CRB&author=Miller%2CV&author=Manegold%2CC&author=Scagliotti%2CG&author=Rosell%2CR&author=Oliff%2CI&author=Reeves%2CJA&author=Wolf%2CMK&author=Krebs%2CAD&author=Averbuch%2CSD&author=Ochs%2CJS&author=Grous%2CJ&author=Fandi%2CA&author=Johnson%2CDH rake in every month?
• How much cash flow does https://doi.org/10.3322%2Fcanjclin.56.2.106 have monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16514137 make?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Cancer%20statistics%2C%202006&journal=CA%20Cancer%20J%20Clin&doi=10.3322%2Fcanjclin.56.2.106&volume=56&pages=106-130&publication_year=2006&author=Jemal%2CA&author=Siegel%2CR&author=Ward%2CE make?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Pretreatment%20clinical%20prognostic%20factors%20in%20patients%20with%20stage%20IV%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20treated%20with%20chemotherapy&journal=J%20Cancer%20Clin%20Oncol&volume=129&pages=114-122&publication_year=2003&author=Jeremic%2CB&author=Milicic%2CB&author=Dagovic%2CA&author=Aleksandrovic%2CJ&author=Nikolic%2CN?
• What's the total monthly financial gain of https://doi.org/10.2307%2F2281868?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Non%20parametric%20estimation%20from%20incomplete%20observations&journal=J%20Am%20Stat%20Assoc&doi=10.2307%2F2281868&volume=53&pages=457-481&publication_year=1958&author=Kaplan%2CEL&author=Meier%2CP
• Financial intake of https://doi.org/10.1002%2F1097-0142%2820011101%2992%3A9%3C2399%3A%3AAID-CNCR1588%3E3.0.CO%3B2-W
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11745296?
• See how much http://scholar.google.com/scholar_lookup?&title=Tumor-related%20leukocytosis%20is%20linked%20with%20poor%20prognosis%20in%20patients%20with%20lung%20carcinoma&journal=Cancer&doi=10.1002%2F1097-0142%2820011101%2992%3A9%3C2399%3A%3AAID-CNCR1588%3E3.0.CO%3B2-W&volume=92&pages=2399-2405&publication_year=2001&author=Kasuga%2CI&author=Makino%2CS&author=Kiyuokawa%2CH&author=Katoh%2CH&author=Ebihara%2CY&author=Ohyashiki%2CK makes per month
• What's the revenue for https://doi.org/10.1200%2FJCO.2002.12.112?
• How much does http://scholar.google.com/scholar_lookup?&title=Paclitaxel%20plus%20carboplatin%20versus%20gemcitabine%20plus%20paclitaxel%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20phase%20III%20randomized%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2002.12.112&volume=17&pages=3578-3585&publication_year=2002&author=Kosmidis%2CP&author=Mylonakis%2CN&author=Nicolaides%2CC&author=Kalophonos%2CC&author=Samantas%2CE&author=Boukovinas%2CJ&author=Fountzilas%2CG&author=Skarlos%2CD&author=Economopoulos%2CT&author=Tsavdaridis%2CD&author=Papakostas%2CP&author=Bacoyiannis%2CC&author=Dimopoulos%2CM make?
• How much income is https://doi.org/10.1200%2FJCO.2004.10.576 earning monthly?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15197195
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20study%20of%20gemcitabine%20and%20vinorelbine%20versus%20gemcitabine%2C%20vinorelbine%20and%20cisplatin%20in%20the%20treatment%20of%20advanced%20non-small-cell%20lung%20cancer%3A%20from%20the%20german%20and%20swiss%20lung%20cancer%20study%20group&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2004.10.576&volume=22&pages=2348-2356&publication_year=2004&author=Laack%2CE&author=Dickgreber%2CN&author=Muller%2CT&author=Knuth%2CA&author=Benk%2CJ&author=Lorenz%2CC&author=Gieseler%2CF&author=Durk%2CH&author=Engel-Riedel%2CW&author=Dalhoff%2CK&author=Kortsik%2CC&author=Graeven%2CU&author=Burk%2CM&author=Dierlamm%2CT&author=Welte%2CT&author=Burkholder%2CI&author=Edler%2CL&author=Hossfeld%2CDK?
• https://doi.org/10.1002%2Fcncr.22049's revenue stream
• Find out how much http://scholar.google.com/scholar_lookup?&title=A%20prognostic%20model%20for%20advanced%20stage%20non-small%20cell%20lung%20cancer&journal=Cancer&doi=10.1002%2Fcncr.22049&volume=107&pages=781-792&publication_year=2006&author=Mandrecar%2CSJ&author=Schild%2CSE&author=Hillman%2CSL&author=Allen%2CKL&author=Marks%2CRS&author=Mailliard%2CJA&author=Krook%2CJE&author=Maksymiuk%2CAW&author=Chansky%2CK&author=Kelly%2CK&author=Adjei%2CAA&author=Jett%2CJR earns monthly
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Prognostic%20factors%20for%20survival%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20univariate%20and%20multivariate%20analyses%20including%20recursive%20partitioning%20and%20amalgamation%20algorithms%20in%201%2C052%20patients&journal=J%20Clin%20Oncol&volume=13&pages=1221-1230&publication_year=1995
• Get to know https://doi.org/10.1038%2Fsj.bjc.6602702's earnings
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16052222
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Elevated%20neutrophil%20and%20monocyte%20counts%20in%20peripheral%20blood%20are%20associated%20with%20poor%20survival%20in%20patients%20with%20metastatic%20melanoma%3A%20a%20prognostic%20model&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6602702&volume=93&pages=273-278&publication_year=2005&author=Schmidt%2CH&author=Bastholt%2CL&author=Geertsen%2CP&author=Christensen%2CIJ&author=Larsen%2CS&author=Gehl%2CJ&author=Maase%2CH?
• How much does https://doi.org/10.1200%2FJCO.2005.01.2781 make?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16293868
• How much does http://scholar.google.com/scholar_lookup?&title=Phase%20III%20trial%20of%20gemcitabine%20plus%20carboplatin%20versus%20single-agent%20gemcitabine%20in%20the%20treatment%20of%20locally%20advanced%20or%20metastatic%20non-small-cell%20lung%20cancer%3A%20the%20Swedish%20lung%20cancer%20study%20group&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2005.01.2781&volume=23&pages=8380-8388&publication_year=2005&author=Sederholm%2CC&author=Hillerdal%2CG&author=Lamberg%2CK&author=Kolbeck%2CK&author=Dufmats%2CM&author=Westberg%2CR&author=Gawande%2CSR generate monthly?
• https://citation-needed.springer.com/v2/references/10.1007/s00432-008-0378-2?format=refman&flavour=references's total income per month
• What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Tibaldi?
• How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Tibaldi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=E.%20Vasile pull in?
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22E.%20Vasile%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=I.%20Bernardini generate?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22I.%20Bernardini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=C.%20Orlandini
• How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22C.%20Orlandini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M.%20Andreuccetti?
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M.%20Andreuccetti%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20Falcone generate?
• Learn how profitable https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20Falcone%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en is on a monthly basis
• See how much https://s100.copyright.com/AppDispatchServlet?title=Baseline%20elevated%20leukocyte%20count%20in%20peripheral%20blood%20is%20associated%20with%20poor%20survival%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%3A%20a%20prognostic%20model&author=C.%20Tibaldi%20et%20al&contentID=10.1007%2Fs00432-008-0378-2©right=Springer-Verlag&publication=0171-5216&publicationDate=2008-03-18&publisherName=SpringerNature&orderBeanReset=true makes per month
• Check the income stats for https://citation-needed.springer.com/v2/references/10.1007/s00432-008-0378-2?format=refman&flavour=citation
• How much income does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral have?
• What's https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research's gross income?
• How much does https://www.springernature.com/gp/products make?
• Get to know https://www.springernature.com/gp/librarians's earnings
• https://www.springernature.com/gp/societies income
• https://www.springernature.com/gp/partners income
• How much does https://www.springer.com/ bring in each month?
• How much does https://www.nature.com/ pull in?
• What are the earnings of https://www.biomedcentral.com/?
• What's the profit of https://www.palgrave.com/?
• How much does https://www.apress.com/ make?
• Income figures for https://www.springernature.com/gp/legal/ccpa
• What's the income generated by https://www.springernature.com/gp/info/accessibility each month?
• How much does https://support.springernature.com/en/support/home earn?
• What's the revenue for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
• https://www.springernature.com/'s financial summary

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref